Page 56 - Read Online

Farlow et al. J Cancer Metastasis Treat 2019;5:18 I http://dx.doi.org/10.20517/2394-4722.2018.100 Page 9 of 10

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.
2. Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist
2010;15:994-1001.
3. Kalinsky K, Hershman DL. Cracking open window of opportunity trials. J Clin Oncol 2012;30:2573-5.
4. Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517:576-82.
5. Hoesli RC, Ludwig ML, Michmerhuizen NL, Rosko AJ, Spector ME, et al. Genomic sequencing and precision medicine in head and neck
cancers. Eur J Surg Oncol 2017;43:884-92.
6. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, et al. The mutational landscape of head and neck squamous cell carcinoma.
Science 2011;333:1157-60.
7. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, et al. Increased epidermal growth factor receptor gene copy number is
associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170-6.
8. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and
neck. N Engl J Med 2006;354:567-78.
9. Schmitz S, Hamoir M, Reychler H, Magremanne M, Weynand B, et al. Tumour response and safety of cetuximab in a window pre-operative
study in patients with squamous cell carcinoma of the head and neck. Ann Oncol 2013;24:2261-6.
10. Ferris RL, Kim S, Trivedi S, Srivastava RM, Concha-Benavente F, et al. Correlation of anti-tumor adaptive immunity with clinical response
in a phase II "window" trial of neoadjuvant cetuximab in ptaients with resectable stage III-IV head and neck squamous carcinoma (HNSCC).
J Clin Oncol 2016;34:6060.
11. Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, et al. STAT1-Induced HLA Class I Upregulation Enhances
Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. Cancer Immunol Res 2015;3:936-45.
12. Thomas F, Rochaix P, Benlyazid A, Sarini J, Rives M, et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and
neck squamous cell carcinoma. Clin Cancer Res 2007;13:7086-92.
13. Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, et al. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind,
placebo-controlled window trial in operable head and neck cancer. Clin Cancer Res 2014;20:3289-98.
14. Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, et al. Randomized, placebo-controlled window trial of EGFR, Src, or combined
blockade in head and neck cancer. JCI Insight 2017;2:e90449.
15. Machiels JP, Bossi P, Menis J, Lia M, Fortpied C, et al. Activity and safety of afatinib in a window preoperative EORTC study in patients
with squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 2018;29:985-91.
16. Uppaluri R, Winkler AE, Lin T, Law JH, Haughey BH, et al. Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to
Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial. Clin Cancer Res 2017;23:2186-94.
17. Day TA, Shirai K, O'Brien PE, Matheus MG, Godwin KB, et al. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head
and Neck Cancer in a Window of Opportunity Trial. Clin Cancer Res 2019;25:1156-64.
18. Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015;33:3293-304.
19. Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head
and Neck. N Engl J Med 2016;375:1856-67.
20. Cohen EEW, Soulieres D, Le Tourneau C, Dinis J, Licitra L, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for
recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet
2019;393:156-67.
21. Timar J, Ladanyi A, Forster-Horvath C, Lukits J, Dome B, et al. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates
intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial. J Clin Oncol 2005;23:3421-32.
22. Wolf GT, Fee WE, Jr., Dolan RW, Moyer JS, Kaplan MJ, et al. Novel neoadjuvant immunotherapy regimen safety and survival in head and
neck squamous cell cancer. Head Neck 2011;33:1666-74.
23. Berinstein NL, McNamara M, Nguyen A, Egan J, Wolf GT. Increased immune infiltration and chemokine receptor expression in head and
neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen. Oncoimmunology 2018;7:e1423173.
24. Uppaluri R, Zolkind P, Lin T, Nussenbaum B, Jackson RS, et al. Neoadjuvant pembrolizumab in surgically resectable, locally advanced
HPV negative head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2017;35:6012.